奥希替尼治疗后，一名具有神经内分泌分化的肺腺癌患者出现NOTCH2-NTRK1融合 - Suppr

Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.

作者信息

Lin Gengpeng, Liu Yangli, Li Hui, Chen Shuyin, Guo Yubiao

机构信息

Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Institute of Pulmonary Diseases, Sun Yat-sen University.

Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University.

出版信息

Clin Lung Cancer. 2021 Sep;22(5):e712-e715. doi: 10.1016/j.cllc.2021.01.015. Epub 2021 Feb 3.

DOI:10.1016/j.cllc.2021.01.015

PMID:33714692

Abstract

摘要

相似文献

Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.奥希替尼治疗后，一名具有神经内分泌分化的肺腺癌患者出现NOTCH2-NTRK1融合

Clin Lung Cancer. 2021 Sep;22(5):e712-e715. doi: 10.1016/j.cllc.2021.01.015. Epub 2021 Feb 3.

Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.奥希替尼治疗后，1例伴有神经内分泌分化的肺腺癌患者出现NOTCH2-NTRK1融合

Clin Lung Cancer. 2021 Mar;22(2):e157-e159. doi: 10.1016/j.cllc.2020.10.003. Epub 2020 Oct 15.

Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma.奥希替尼对表皮生长因子受体（EGFR）第20外显子插入阳性肺腺癌的疗效

J Thorac Oncol. 2018 Oct;13(10):e204-e206. doi: 10.1016/j.jtho.2018.05.017.

EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib.表皮生长因子受体突变型肺腺癌伴抗合成酶综合征经奥希替尼治疗成功。

Thorac Cancer. 2021 May;12(9):1441-1444. doi: 10.1111/1759-7714.13920. Epub 2021 Mar 7.

Successful osimertinib retreatment after extremely early onset severe pneumonitis in first-line treatment of lung adenocarcinoma.奥希替尼二线治疗肺腺癌一线治疗中极早发生严重肺炎后的成功治疗。

Thorac Cancer. 2020 Sep;11(9):2713-2716. doi: 10.1111/1759-7714.13565. Epub 2020 Jul 15.

Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.一名患有罕见表皮生长因子受体（EGFR）突变的肺腺癌患者在对奥希替尼产生获得性耐药后发生鳞状细胞癌转化。

J Formos Med Assoc. 2020 Sep;119(9):1439-1441. doi: 10.1016/j.jfma.2019.12.017. Epub 2020 Mar 12.

Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation.奥希替尼治疗双EGFR L747S和G719C突变患者的临床疗效

J Thorac Oncol. 2019 Jul;14(7):e151-e153. doi: 10.1016/j.jtho.2019.02.034.

Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells.Hsa_circ_0005576 通过 miR-512-5p/IGF1R 轴促进肺腺癌细胞对奥希替尼的耐药性。

Cancer Sci. 2022 Jan;113(1):79-90. doi: 10.1111/cas.15177. Epub 2021 Nov 15.

Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib.通过循环肿瘤DNA分析对接受奥希替尼治疗的表皮生长因子受体（EGFR）突变型肺腺癌患者的多种耐药机制进行早期检测

Clin Lung Cancer. 2020 Sep;21(5):e488-e492. doi: 10.1016/j.cllc.2020.03.009. Epub 2020 Apr 9.

Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.在一名患有EGFR L718Q突变的非小细胞肺癌患者中使用阿法替尼解决对奥希替尼治疗的耐药性

Clin Lung Cancer. 2020 Jul;21(4):e258-e260. doi: 10.1016/j.cllc.2019.12.002. Epub 2020 Jan 23.

引用本文的文献

Genetic and oncogenic features of RASGRF fusions.RASGRF融合基因的遗传和致癌特征。

NPJ Precis Oncol. 2025 Jul 5;9(1):224. doi: 10.1038/s41698-025-01017-1.

Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology.超越临床试验：理解神经营养素受体络氨酸激酶抑制剂在真实世界儿科肿瘤学中的挑战和疗效。

JCO Precis Oncol. 2024 May;8:e2300713. doi: 10.1200/PO.23.00713.

Primary Resistance to Larotrectinib in a Patient With Squamous NSCLC With Subclonal Fusion: Case Report.一名伴有亚克隆融合的肺鳞状非小细胞肺癌患者对拉罗替尼的原发性耐药：病例报告

JTO Clin Res Rep. 2023 Mar 17;4(4):100501. doi: 10.1016/j.jtocrr.2023.100501. eCollection 2023 Apr.

TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by Fusions.Merkel 细胞癌中 TRK 蛋白的表达并非由融合引起。

Int J Mol Sci. 2022 Dec 6;23(23):15366. doi: 10.3390/ijms232315366.

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.奥希替尼耐药后，联合使用奥希替尼再挑战和恩曲替尼对一名获得性LMNA-NTRK1融合的EGFR突变非小细胞肺癌患者的生存获益。

Respirol Case Rep. 2022 Oct 17;10(11):e01054. doi: 10.1002/rcr2.1054. eCollection 2022 Nov.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献